Beijing Institute of Hepatology is a municipal public welfare research institution dedicated to basic research and clinical translation in liver diseases, with a mission to drive scientific innovation and serve patients with liver conditions. Currently, the institute houses four PI research teams and six technology platforms. The PI teams work in an integrated manner with Co-PI teams from partner hospital-Beijing You An Hospital, focusing on key research areas including "Liver Disease and Tumor Metabolism," "Fatty Liver Disease and Fibrosis," "Liver Failure and Regeneration," and "Liver Cancer and Transplantation."

The technology platforms encompass nucleic acid sequencing, protein research, flow cytometry, cellular and tissue morphology and function, experimental animal models, and diagnostic antibody development. The institute is equipped with cutting-edge international instruments such as single-cell sequencers, next-generation sequencers, mass cytometry, quantitative imaging flow cytometers, liquid chromatography-mass spectrometers, super-resolution confocal microscopes, small animal multimodal in vivo imaging systems, and animal metabolic monitoring systems. It also operates a P2 laboratory and an SPF-grade animal facility with individually ventilated cages (IVC). As a member of the Beijing Engineering Technology Research Center and the Capital Science and Technology Condition Platform, the institute leverages the specialized hepatology expertise of Beijing YouAn Hospital to expand the scope of liver disease research. By closely integrating clinical practice with fundamental research and utilizing its six core technology platforms as a public service framework, the institute aims to advance scientific discovery, enhance clinical diagnosis and treatment, improve comprehensive disease management, and ultimately contribute to better patient care, the development of Beijing's healthcare system, and the improvement of public health.